For the use only of Physician, Gynaecologist, Oncologist,
Leuprolide Acetate for Injection 11.25 mg (Depot)
11.25 mg

(3 months Depot)

For Intramuscular / Subcutaneous use
For Single use only
Not for Intravenous Administration
(DEPOT) 11.25 mg is a sterile lyophilized containing Leuprolide Acetate
formulated as Microspheres. LUPRODEXTM (DEPOT) 11.25 mg is to be reconstituted with
accompanying diluent which forms a uniform suspension, intended for intramuscular or
subcutaneous injection to be administered once every three months.
Leuprolide Acetate is a synthetic nonapeptide analog of naturally occurring gonadotropin-
releasing hormone (GnRH or LH-RH). The analog possesses greater potency than the natural
1. LUPRODEXTM (DEPOT) 11.25 mg:
Each vial contains:
Leuprorelin B.P. (As acetate) . 11.25 mg
Excipients : Polylactic acid, Mannitol I.P.
2. Ampoule of diluent for reconstitution:
Each mL contains:
Mannitol I.P. . 50 mg
Water for Injection I.P. . q.s.
Other Excipients : Sodium Carboxymethyl Cellulose I.P. Polysorbate-80 I.P., Glacial acetic
acid U.S.P.

Leuprolide Acetate, a GnRH agonist, acts as a potent inhibitor of gonadotropin secretion when
given continuously and in therapeutic doses. Human studies indicate that following an initial
stimulation of gonadotropins, chronic stimulation with Leuprolide Acetate results in suppression
or “down-regulation” of these hormones and consequent suppression of ovarian and testicular
steroidogenesis. These effects are reversible on discontinuation of drug therapy.
Leuprolide Acetate is not active when given orally.
Intramuscular injection of the depot formulation provides plasma concentrations of Leuprolide
over a period of three months.
Distribution: Distributed to kidney, liver, pineal and pituitary tissues.
Metabolism: it is metabolized into its metabolites in hypothalamus and anterior pituitary gland.
Elimination: Leuprolide is eliminated by enzymatic breakdown and renal excretion.
When used three monthly at the recommended dose, LUPRODEXTM (DEPOT) 11.25 mg
usually inhibits ovulation and stops menstruation. Contraception is not insured, however, by
taking LUPRODEXTM (DEPOT) 11.25 mg. Therefore, patients should use non-hormonal
methods of contraception.
Patients should be advised to see their physician if they believe they may be pregnant. If a
patient becomes pregnant during treatment, the drug must be discontinued and the patient must
be apprised of the potential risk to the fetus.
During the early phase of therapy, sex steroids temporarily rise above baseline because of the
physiologic effect of the drug. Therefore, an increase in clinical signs and symptoms may be
observed during the initial days of therapy, but these will dissipate with continued therapy.
LUPRODEXTM (DEPOT) 11.25 mg is indicated in the treatment of endometriosis, including pain
relief and reduction of endometriosis lesions. Duration of initial treatment or retreatment should
be limited to 6 months.
LUPRODEXTM (DEPOT) 11.25 mg can be used as sole therapy where it may provide
symptomatic relief for women close to menopause who do not desire surgery, or as an adjunct
to surgery.
Uterine Leiomyomata (Fibroids):
LUPRODEXTM (DEPOT) 11.25 mg concomitantly with iron therapy is indicated for the
preoperative hematologic improvement of patients with anemia caused by uterine leiomyomata.
LUPRODEXTM (DEPOT) 11.25 mg may be added if the response to iron alone is considered
inadequate. Recommended duration of therapy with LUPRODEXTM (DEPOT) 11.25 mg is up to
six months.

Advanced Prostate Cancer (Palliative Treatment):
LUPRODEXTM (DEPOT) 11.25 mg is indicated in the treatment of advanced prostatic cancer. It
offers an alternative treatment of prostatic cancer when orchidectomy or estrogen
administration are either not indicated or unacceptable to the patient.

1. Hypersensitivity to GnRH, GnRH agonist analogs or its diluent.
2. Undiagnosed abnormal vaginal bleeding.
3. LUPRODEXTM (DEPOT) 11.25 mg is contraindicated in women who are pregnant while
receiving the drug. LUPRODEXTM (DEPOT) 11.25 mg may cause fetal harm when administered
to a pregnant woman.
4. Use in women who are breast-feeding.

'Flare phenomenon' is the commonly occurring side effect of Leuprolide (symptoms of hot
flushes; sweats; peripheral oedema; GI upset). Temporary increase in the degree of bone pain
and obstructive voiding symptoms have been noted within the first 72 hours of therapy. This
may occur due to increased testosterone level during the first week of treatment. Concomitant
administration of an androgen antagonist like flutamide prevents the flare phenomenon in male
Long Term usage leading to decreased bone density has been reported in the medical literature
in men who have had orchiectomy or who have been treated with an LH-RH agonist analog. In
a clinical trial, 25 men with prostate cancer, 12 of whom had been treated previously with
leuprolide acetate for at least six months, underwent bone density studies as a result of pain.
The leuprolide-treated group had lower bone density scores than the non- treated control group.
It can be anticipated that long periods of medical castration in men will have effects on bone
Anaphylactoid or asthmatic process have been rarely reported.
Rash, urticaria, and photosensitivity reactions have also been reported.
Also a localized reaction including induration and abscess at the site of injection.
Symptoms consistent with fibromyalgia (eg: joint and muscle pain, headaches, sleep disorder,
gastrointestinal distress, and shortness of breath) have been reported.
Other reactions reported are:
 Cardiovascular System - Hypotension, Pulmonary embolism;
 Blood & Lymphatic System - Decreased WBC;  Nervous System - Peripheral neuropathy, Spinal fracture / paralysis;  Musculoskeletal System - Tenosynovitis like symptoms;  Urogenital System - Prostate pain.

Safe use of leuprolide acetate in pregnancy has not been established clinically. Before starting
treatment with LUPRODEXTM (DEPOT) 11.25 mg, pregnancy must be excluded.
Assessment and management of risk factors for cardiovascular disease is recommended prior
to initiation of add-back therapy with norethindrone acetate. Norethindrone acetate should be
used with caution in women with risk factors, including lipid abnormalities or cigarette smoking.
Monitoring in Advanced Prostatic Cancer Patients:
Closely observe prostatic cancer patients with metastatic vertebral lesions or with urinary tract
obstruction during first few weeks of therapy. Monitor therapeutic response by measuring
testosterone serum levels, prostate-specific antigen (PSA), and prostatic acid phosphatase.
Verify down-regulation in patients whose weight has increased significantly while on therapy.
Monitor measurements of bone age for advancement every 6 to12 months.
Worsening of signs or symptoms during the first weeks of treatment have been reported.
Worsening of symptoms may contribute to paralysis with or without fatal complications. Patients
with metastatic vertebral lesions and/or with urinary tract obstruction should be closely observed
during the first few weeks of treatment.
Drug / Laboratory Test Interactions:
Administration of LUPRODEXTM (DEPOT) 11.25 mg in therapeutic doses results in suppression
of the pituitary-gonadal system. Normal function is usually restored within three months after
treatment is discontinued. Therefore, diagnostic tests of pituitary gonadotropic and gonadal
functions conducted during treatment and for up to three months after discontinuation of
LUPRODEXTM (DEPOT) 11.25 mg may be misleading.
Low HDL-cholesterol (<40 mg/dL) and elevated LDL-cholesterol (>160 mg/dL) are recognized
risk factors for cardiovascular disease. The long-term significance of the observed treatment
related changes in serum lipids in women with endometriosis is unknown. Therefore
assessment of cardiovascular risk factors should be considered prior to initiation of concurrent
treatment with LUPRODEXTM (DEPOT) 11.25 mg and norethindrone acetate. If additional
treatment (duration longer than 3 months) with LUPRODEXTM (DEPOT) 11.25 mg is
contemplated, bone density should be assessed prior to initiation of therapy to ensure that
values are within normal limits.
Pediatric Use: Experience with LUPRODEXTM (DEPOT) 11.25 mg for treatment of
endometriosis has been limited to women 18 years of age and older.

(DEPOT) 11.25 mg must be administered under the supervision of a physician.
Endometriosis: The recommended duration of treatment with LUPRODEXTM (DEPOT) 11.25 mg
alone or in combination with norethindrone acetate is six months. The choice of LUPRODEXTM
(DEPOT) 11.25 mg alone or LUPRODEXTM (DEPOT) 11.25 mg plus norethindrone acetate
therapy for initial management of the symptoms and signs of endometriosis should be made by
the health care professional in consultation with the patient and should take into consideration
the risks and benefits of the addition of norethindrone to LUPRODEXTM (DEPOT) 11.25 mg
If the symptoms of endometriosis recur after a course of therapy, retreatment with a six month
course of LUPRODEXTM (DEPOT) 11.25 mg three monthly and norethindrone acetate 5 mg
daily may be considered. Retreatment beyond this one six-month course cannot be
recommended. It is recommended that bone density be assessed before retreatment begins to
ensure that values are within normal limits. LUPRODEXTM (DEPOT) 11.25 mg alone is not
recommended for retreatment. If norethindrone acetate is contraindicated for the individual
patient, then retreatment is not recommended.
An assessment of cardiovascular risk factors such as cigarette smoking is recommended before
beginning treatment with LUPRODEXTM (DEPOT) 11.25 mg and norethindrone acetate.
Uterine Leiomyomata (Fibroids): Recommended duration of therapy with LUPRODEXTM
(DEPOT) 11.25 mg is up to 3 months. The symptoms associated with uterine leiomyomata will
recur following discontinuation of therapy. If additional treatment with LUPRODEXTM (DEPOT)
11.25 mg is contemplated, bone density should be assessed prior to initiation of therapy to
ensure that values are within normal limits.
Prostate cancer: Administered three monthly as a single intramuscular injection. Therapy should
not be discontinued when remission or improvement occurs.
Reconstitution & Administration for LUPRODEXTM (DEPOT) 11.25 mg:
 Use Aseptic Precautions throughout.
 Do not substitute saline or sterile water for diluent.
(please refer diagram for the reconstitution details on the back side).
1. Ensure that the diluent fluid is at the bottom section of the ampoule of diluent. Open the
ampoule from the tip.
2. Using a syringe with 22 gauge needle, withdraw 1.5 ml of diluent from the ampoule. (Extra
diluent is provided; any remaining unused portion should be discarded).
3. Remove the plastic seal cap from the vial.
4. Inject the diluent from the syringe into the glass vial.
5. Shake well for thorough dispersion of particles to obtain a uniform suspension. (The
suspension will appear milky).
6. Withdraw entire contents from the vial into the syringe.
7. Inject intramuscularly / subcutaneously.
8. Discard the unused product remaining in the vial along with the unused diluent remaining in
the ampoule.
The product has been shown to be stable for 24 hours following reconstitution. Since the
product does not contain a preservative, the reconstituted product should be discarded if not
used immediately.
In rats subcutaneous administration of 250 to 500 times the recommended human dose,
expressed on a per body weight basis, resulted in dyspnea, decreased activity, and local
irritation at the injection site. There is no evidence that there is a clinical counterpart of this
phenomenon. In early clinical trials using daily subcutaneous Leuprolide Acetate in patients with
prostate cancer, doses as high as 20 mg/day for up to two years caused no adverse effects
differing from those observed with the 1 mg/day dose.
Store below 250C. Do not freeze.
Each pack of LUPRODEXTM (DEPOT) 11.25 mg is supplied as one vial containing
microspheres equivalent to 11.25 mg of Leuprolide Acetate along with one ampoule of diluent
for reconstitution, one disposable syringe, two needles and two alcohol swabs.

i) Sean C. Sweetman, Martindale : The Complete Drug Reference, 34th Edition, 2005, The
Pharmaceutical Press, 1331.
ii) Sennello LT, et al. Single dose pharmacokinetic of Leuprolide in humans following
intravenous and subcutaneous administration.
J Pharm Sci 1986; 75:158-60.

iii) Takeuchi H, et al. A prospective randomized study comparing endocrinological and clinical
effects of two types of GnRH agonists in cases of uterine leiomyomas or endometriosis.
J Obstet Gynaecol Res 2000; 26:325-31.

iv) Hiroaki Okada, One and three-months release injectable microspheres of the LH-RH
superagonist leuprorelin acetate.
Adv Drug Del Rev 1997; 28:43-47.

v) Seidenfeld J, et al. Single-therapy androgen suppression in men with advanced prostate
cancer: a systemic review and meta-analysis.
Ann Intern Med 2000; 132:566-77.

vi) Carel JC, et al. Treatment of central precocious puberty with depot leuprorelin.
Eur J Endocrinol 1995; 132:699-704.

Manufactured in India by :
Plot No. K-27, Additional M.I.D.C., Ambernath (E) - 421 501
Procedure for Reconstitution:
Use Aseptic Technique Throughout
Do not use Sterile Water for Injection or Sodium Chloride Injection (Saline) for
reconstitution in place of the recommended diluent provided with this pack.
1) Visually inspect the vial. Vial should not be used if clumping or caking is evident. A thin layer of powder on the wall of the vial is considered normal. The diluent in the ampoule should appear clear. Ensure that the fluid is at the bottom section of the ampoule (flick or tap lightly if need be). Hold the ampoule and snap open the ampoule as shown in the picture. 2) Use luer lock syringe with 22 gauge needle provided with this pack. Fix needle in luer lock till it rotates no more. Withdraw 1ml of diluent from the ampoule. 3) Remove plastic seal cap of vial by flicking it off. 4) Inject diluent into the vial. 5) Shake well the contents of vial for thorough Dispersion. The suspension will appear uniformly milky. 6) Withdraw entire contents of the vial back in the syringe. Inject intramuscularly / subcutaneously. Discard the remainder of the diluent, the ampoule and the vial.



Sicherheitsdatenblatt gemäß 1907/2006/EG, Artikel 31 Druckdatum: 28.11.2013 überarbeitet am: 28.11.2013 1 Bezeichnung des Stoffes/der Zubereitung und des Unternehmens · Angaben zum Produkt · Handelsname: Salzsäure 32% · Verwendung des Stoffes / der Zubereitung Reinigungsmittel sauer · Hersteller/Lieferant: Labulit AGPilatusstrasse 31CH-5630 Muri AGTel +41 (0)44 261 6

42104 clarizio_postop instrucs

Diplomate, American Board of Oral & Maxillofacial Surgery GENERAL POSTOPERATIVE INSTRUCTIONS We are committed to providing the same quality of care following procedures that began during your initial visit. To that end, please refer to some general postoperative guidelines below, and by all means, CALL at any hour of any day to report any continuing problem. 1. FLUID AND FOOD INTAKE IS

Copyright © 2010 Medicament Inoculation Pdf